Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03433911 · ClinicalTrials.gov registry record · NA
FemBloc® Permanent Contraception - Early Pivotal Trial
A NA study of Contraception, sponsored by Femasys.
- Completed
- Registry status
- NA
- Development phase
- 240
- Enrollment target
- 12
- Study locations
NCT03433911: Completed NA study of Contraception, sponsored by Femasys.
NCT03433911 is a NA study of Contraception that has completed, run by Femasys. The registered enrollment target is 240 participants, below the 451-participant average among 72 other Contraception trials with a reported enrollment target (47% lower). The trial reports 12 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03433911, a NA study of Contraception, has completed, sponsored by Femasys.
- COMPLETED
- Registry status
- NA
- Development phase
- 240 participants
- Enrollment target
- 12
- Study locations
Study Summary
Prospective, multi-center, international, non-randomized, two-arm study of subjects undergoing either FemBloc or laparoscopic bilateral tubal sterilization (Control). The FemBloc group total study duration will be approximately 65 months. The laparoscopic tubal sterilization (Control) group total study duration will be approximately 62 months.
Primary Outcome
Safety: Incidence of short-term and long-term adverse events in each arm
Conditions Studied
Interventions
- DEVICE FemBloc
- PROCEDURE Laparoscopic bilateral tubal sterilization
Study Locations (12)
Ohio
- University Hospitals Cleveland Medical Center - Beachwood
- Amy Brenner MD & Associates - Mason
Arizona
- New Horizons Clinical Trials - Chandler
California
- Stanford University - Stanford
Florida
- Altus Research Inc. - Lake Worth
Idaho
- Rosemark Womencare Specialists - Idaho Falls
Indiana
- Women's Health Advantage - Fort Wayne
New Jersey
- Rutgers, The State University of New Jersey - Newark
New York
- Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2018-02-02 |
| Est. Completion | 2025-02-10 |
| Phase | NA |
What the finished NCT03433911 record still lists
NCT03433911 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 451-participant average among 72 other Contraception trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Contraception appearing as the primary indexed condition, and to 2 interventions - of which FemBloc is the first listed.
NCT03433911 lists 12 locations in 11 states (Ohio, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT03433911 about?
NCT03433911 is a clinical study titled "FemBloc® Permanent Contraception - Early Pivotal Trial". Prospective, multi-center, international, non-randomized, two-arm study of subjects undergoing either FemBloc or laparoscopic bilateral tubal sterilization (Control). The FemBloc group total study duration will be approximately 65 months. The laparoscopic tubal sterilization (Control) group total st...
What is the current status of trial NCT03433911?
This trial is currently completed. It is a NA study. The enrollment target is 240 participants. The study started on 2018-02-02. Estimated completion is 2025-02-10.
What conditions does trial NCT03433911 study?
This clinical trial studies the following conditions: Contraception.
What interventions are being tested in trial NCT03433911?
The interventions under investigation include: FemBloc (DEVICE), Laparoscopic bilateral tubal sterilization (PROCEDURE).
Who is sponsoring clinical trial NCT03433911?
This trial is sponsored by Femasys, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03433911 being conducted?
This trial has 12 study locations across Arizona, California, Florida, Idaho, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contraception
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03433911's enrollment target sits among peer trials
240 31st of 72 higher than 42 of 72 other Contraception trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Contraception trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Patient-clinical Linkages to Improve Trust and Engagement in Postpartum Healthcare
RECRUITING · NA
-
Empathy Through Pain Control: Lidocaine Paracervical Block for IUD Placements
RECRUITING · NA
-
Hormonal Contraception Access Through Pharmacist Prescribing Implementation
RECRUITING · NA
-
Prospective Multi-Center Trial for FemBloc Permanent Birth Control
RECRUITING · NA
-
Contraceptive Efficacy Study of Ovaprene
RECRUITING · NA
-
Intervening on Women's Health for Rural Young Cancer Survivors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI